Proficio Capital Partners LLC bought a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 54,717 shares of the company’s stock, valued at approximately $2,365,000. Proficio Capital Partners LLC owned 0.06% of Scholar Rock as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently made changes to their positions in SRRK. Intech Investment Management LLC acquired a new stake in shares of Scholar Rock in the third quarter valued at about $202,000. Charles Schwab Investment Management Inc. increased its stake in Scholar Rock by 9.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock valued at $4,027,000 after purchasing an additional 42,139 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Scholar Rock by 593.6% during the third quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock worth $5,879,000 after purchasing an additional 628,186 shares during the last quarter. FMR LLC boosted its position in Scholar Rock by 3.1% during the third quarter. FMR LLC now owns 10,196,046 shares of the company’s stock worth $81,670,000 after purchasing an additional 308,813 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Scholar Rock by 900.6% in the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company’s stock valued at $291,000 after purchasing an additional 32,700 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.
Scholar Rock Stock Performance
Shares of SRRK opened at $33.88 on Wednesday. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -14.42 and a beta of 0.59. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company’s 50 day simple moving average is $39.17 and its 200 day simple moving average is $31.85.
Analysts Set New Price Targets
Check Out Our Latest Report on SRRK
Insiders Place Their Bets
In related news, insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the completion of the transaction, the insider now directly owns 67,200 shares in the company, valued at approximately $2,970,240. This represents a 7.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at approximately $3,966,108.90. The trade was a 56.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 292,266 shares of company stock valued at $10,996,151 in the last quarter. 19.20% of the stock is currently owned by company insiders.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
See Also
- Five stocks we like better than Scholar Rock
- What is the S&P/TSX Index?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Must-Own Stocks to Build Wealth This Decade
- What Are Some of the Best Large-Cap Stocks to Buy?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.